Skip to content
drillr.ai
Sign up

ENVB

Enveric Biosciences, Inc.

NASDAQ · Healthcare · Biotechnology · US

$1.39
−3.47%
Ask drillr

  • Aug 14, 2026, 00:00 UTC

    Enveric Biosciences raised $5.0 million in gross proceeds from a private placement and $1.5 million from warrant exercises during Q2 2026, with potential additional proceeds of $8.9 million from full warrant exercise.

  • Aug 14, 2026, 00:00 UTC

    Enveric Biosciences reported a net loss of $3.0 million for Q2 2026, compared to a net loss of $2.5 million in Q2 2025, with cash on hand of $8.3 million as of June 30, 2026.

  • Aug 5, 2026, 13:30 UTC

    Enveric Biosciences announced new preclinical data confirming the non-hallucinogenic profile of its lead psychiatric drug candidate EB-003.

    Source:

  • Jun 2, 2026, 12:00 UTC

    Enveric Biosciences initiated IND-enabling genotoxicity studies of its lead neuroplastogen candidate EB-003.

    Source: